title: Effect of proton-pump inhibitor therapy on serum chromogranin a level.
abstract: BACKGROUND
  The neuroendocrine marker, chromogranin A (CgA) increases during medium- or long-term proton-pump inhibitor (PPI) treatment.
  
  
  OBJECTIVE
  To analyze the effect of ultra-short-term and diverse dose of PPI therapy on serum CgA and gastrin levels and evaluate the effect of PPI treatment cessation.
  
  
  METHODS
  Fasting serum CgA and gastrin were determined in newly diagnosed gastroesophageal reflux disease (GERD) patients (n = 54) treated with diverse doses of PPI during a 28-day period, in patients treated with PPIs for at least 6 months (n = 42), and in subjects where PPI treatment could be stopped (n = 11).
  
  
  RESULTS
  A significant stepwise increase of CgA levels was observed after 5 days during the 28-day period treatment with all PPI doses. Gastrin increased significantly also in the standard and high-dose PPI subgroups. The most prominent increase of CgA was observed in the high-dose PPI subgroup. Serum CgA and gastrin were markedly elevated after 6 months of PPI treatment, and decreased significantly after 5 days of PPI discontinuation.
  
  
  CONCLUSIONS
  Serum CgA increases significantly even after ultra-short-term (5 days) PPI therapy. After long-term treatment, 5-day cessation of PPI therapy is sufficient to decrease significantly both CgA and gastrin levels.
authors.affiliation: 2nd Department of Medicine, Semmelweis University, and Gastroenterology and Endocrinology Unit, Hungarian Academy of Sciences, Budapest, Hungary. pregunistvan @ yahoo.com
authors.forename: István
authors.initials: I
authors.lastname: Pregun
authors.forename: László
authors.initials: L
authors.lastname: Herszényi
authors.forename: Márk
authors.initials: M
authors.lastname: Juhász
authors.forename: Pál
authors.initials: P
authors.lastname: Miheller
authors.forename: István
authors.initials: I
authors.lastname: Hritz
authors.forename: Attila
authors.initials: A
authors.lastname: Patócs
authors.forename: Károly
authors.initials: K
authors.lastname: Rácz
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Tulassay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D053379:Chromogranin A / Q000097:blood* / Q000187:drug effects; D005260:Female; D005755:Gastrins / Q000097:blood* / Q000187:drug effects; D005764:Gastroesophageal Reflux / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D013997:Time Factors; D055815:Young Adult
chemical_list: D053379:Chromogranin A; D005755:Gastrins; D054328:Proton Pump Inhibitors